Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Rating Lowered by Wolfe Research

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) was downgraded by investment analysts at Wolfe Research from a "peer perform" rating to an "underperform" rating in a research report issued to clients and investors on Tuesday, MarketBeat reports.

Other equities analysts also recently issued research reports about the company. Bank of America boosted their target price on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the stock a "buy" rating in a research note on Monday, October 14th. Barclays upped their price objective on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the company an "overweight" rating in a research note on Friday, November 1st. Raymond James raised their target price on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Scotiabank boosted their price target on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the stock a "sector outperform" rating in a report on Friday, November 1st. Finally, TD Cowen raised their price objective on shares of Alnylam Pharmaceuticals from $282.00 to $371.00 and gave the stock a "buy" rating in a report on Monday, October 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus target price of $294.50.

Alnylam Pharmaceuticals Stock Down 4.1 %

Shares of NASDAQ:ALNY traded down $11.43 during trading on Tuesday, reaching $268.39. 307,396 shares of the stock were exchanged, compared to its average volume of 869,872. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The stock has a fifty day moving average of $274.52 and a two-hundred day moving average of $232.41. The company has a debt-to-equity ratio of 31.64, a current ratio of 2.75 and a quick ratio of 2.69. The firm has a market cap of $34.62 billion, a price-to-earnings ratio of -106.80 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.36). The firm had revenue of $500.90 million for the quarter, compared to analysts' expectations of $532.91 million. During the same period in the prior year, the company earned $1.15 EPS. Alnylam Pharmaceuticals's revenue was down 33.3% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals will post -2.22 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 15,000 shares of the firm's stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $280.00, for a total value of $4,200,000.00. Following the sale, the chief executive officer now owns 73,441 shares of the company's stock, valued at $20,563,480. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its holdings in shares of Alnylam Pharmaceuticals by 0.4% in the first quarter. Vanguard Group Inc. now owns 11,994,261 shares of the biopharmaceutical company's stock worth $1,792,542,000 after buying an additional 50,366 shares during the period. Price T Rowe Associates Inc. MD grew its holdings in shares of Alnylam Pharmaceuticals by 5.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 3,685,753 shares of the biopharmaceutical company's stock worth $550,837,000 after purchasing an additional 201,784 shares during the last quarter. Capital International Investors increased its stake in shares of Alnylam Pharmaceuticals by 1.8% in the first quarter. Capital International Investors now owns 3,651,217 shares of the biopharmaceutical company's stock worth $545,674,000 after buying an additional 64,560 shares during the period. Capital Research Global Investors raised its holdings in Alnylam Pharmaceuticals by 7.3% during the 1st quarter. Capital Research Global Investors now owns 3,144,987 shares of the biopharmaceutical company's stock valued at $470,018,000 after buying an additional 214,908 shares during the last quarter. Finally, Bellevue Group AG raised its holdings in Alnylam Pharmaceuticals by 3.7% during the 1st quarter. Bellevue Group AG now owns 918,284 shares of the biopharmaceutical company's stock valued at $137,238,000 after buying an additional 32,966 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.